Sarepta Plots Multi-Study Label Expansion For Elevidys To Eventually Cover Nearly All DMD Population

Studies supporting label expansion already are under way, with more targeting those currently ineligible, including boys with pre-existing antibodies, set to begin later this year, after the initial accelerated approval only allowed use in four- and five-year old patients.